Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2026)

Recursion Pharmaceuticals' Non Operating Income history runs 7 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• Quarterly Non Operating Income rose 156.73% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (up 1774.22% YoY) and the FY2025 annual result came in at $3.2 million, down 77.23% from the prior year.
• Non Operating Income was $6.4 million for Q1 2026 at Recursion Pharmaceuticals, up from $232000.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $10.0 million in Q3 2025 and bottomed at -$11.3 million in Q1 2025.
• A 5-year average of $2.8 million and a median of $3.5 million in 2022 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 226800.0% — and 2025, when it sank 369.27%.
• Recursion Pharmaceuticals' Non Operating Income stood at $3.5 million in 2022, then tumbled by 46.36% to $1.9 million in 2023, then jumped by 160.1% to $4.9 million in 2024, then sank by 95.24% to $232000.0 in 2025, then jumped by 2657.33% to $6.4 million in 2026.
• Business Quant data shows RXRX's Non Operating Income at $6.4 million in Q1 2026, $232000.0 in Q4 2025, and $10.0 million in Q3 2025.